Literature DB >> 29166308

An Evaluation of the Choice for Contralateral Prophylactic Mastectomy and Patient Concerns About Recurrence in a Reconstructed Cohort.

Ian C Sando, Jessica I Billig, Shoshana W Ambani, Casey T Kraft, Kelley M Kidwell, Lin Zhong, Kevin C Chung, Adeyiza O Momoh.   

Abstract

BACKGROUND: Rising contralateral prophylactic mastectomy rates are a subject of national concern. This study assessed (1) factors critical to patients when deciding on contralateral prophylactic mastectomy and (2) patients' quality of life related to concerns about recurrence after unilateral or bilateral breast reconstruction.
METHODS: Patients with stage 0 to III breast cancer who underwent unilateral mastectomy or contralateral prophylactic mastectomy and breast reconstruction at a single institution between 2000 and 2012 were identified. Demographic and clinical data were extracted by chart review. Women's fears about breast cancer recurrence were assessed using the Concerns About Recurrence Scale, and motivational factors for contralateral prophylactic mastectomy were identified using the Decisions for Contralateral Prophylactic Mastectomy Survey.
RESULTS: Survey responses were received from 157 patients (59%) who underwent unilateral reconstruction and 109 (41%) who underwent bilateral reconstruction. The top 3 reasons for choosing contralateral prophylactic mastectomy were (1) decreasing the risk of contralateral breast disease (97%), (2) peace of mind (96%), and (3) improved survival (93%). Women who chose contralateral prophylactic mastectomy reported significantly greater overall fear and worry compared with the unilateral group, specifically, greater fears of dying and worries about adequately fulfilling roles of daily life (P < 0.05).
CONCLUSIONS: Despite no proven survival benefit, women chose contralateral prophylactic mastectomy primarily to optimize oncologic outcomes. Among breast reconstruction patients, women who underwent contralateral prophylactic mastectomy had greater anxiety and overall fear of breast cancer recurrence compared with those who chose unilateral mastectomy. These findings are important to consider when counseling women contemplating contralateral prophylactic mastectomy.

Entities:  

Mesh:

Year:  2018        PMID: 29166308     DOI: 10.1097/SAP.0000000000001258

Source DB:  PubMed          Journal:  Ann Plast Surg        ISSN: 0148-7043            Impact factor:   1.539


  6 in total

1.  Factors Affecting Surgical Decisions in Newly Diagnosed Young Women with Early-Stage Breast Cancer.

Authors:  Shoshana M Rosenberg; Mary L Greaney; Andrea F Patenaude; Ann H Partridge
Journal:  J Adolesc Young Adult Oncol       Date:  2019-04-03       Impact factor: 2.223

Review 2.  Contralateral prophylactic mastectomy and implications for breast reconstruction.

Authors:  Katherine B Santosa; Jeremie D Oliver; Adeyiza O Momoh
Journal:  Gland Surg       Date:  2021-01

3.  Longitudinal Study of Psychosocial Outcomes Following Surgery in Women with Unilateral Nonhereditary Breast Cancer.

Authors:  David W Lim; Helene Retrouvey; Isabel Kerrebijn; Kate Butler; Anne C O'Neill; Tulin D Cil; Toni Zhong; Stefan O P Hofer; David R McCready; Kelly A Metcalfe
Journal:  Ann Surg Oncol       Date:  2021-04-05       Impact factor: 5.344

4.  Trends in Contralateral Prophylactic Mastectomy Utilization for Small Unilateral Breast Cancer.

Authors:  Alison S Baskin; Ton Wang; Brooke C Bredbeck; Brandy R Sinco; Nicholas L Berlin; Lesly A Dossett
Journal:  J Surg Res       Date:  2021-02-03       Impact factor: 2.417

5.  Predictive Analytics for Inpatient Postoperative Opioid Use in Patients Undergoing Mastectomy.

Authors:  Isabella M Dolendo; Anne M Wallace; Ava Armani; Ruth S Waterman; Engy T Said; Rodney A Gabriel
Journal:  Cureus       Date:  2022-03-11

6.  Surgical Decision-Making Surrounding Contralateral Prophylactic Mastectomy: Comparison of Treatment Goals, Preferences, and Psychosocial Outcomes from a Multicenter Survey of Breast Cancer Patients.

Authors:  Ingrid M Lizarraga; Mary C Schroeder; Ismail Jatoi; Sonia L Sugg; Amy Trentham-Dietz; Laurel Hoeth; Elizabeth A Chrischilles
Journal:  Ann Surg Oncol       Date:  2021-07-12       Impact factor: 5.344

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.